RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
Glen Rock, N.J., Nov. 17, 2022 -- RespireRx Pharmaceuticals Inc. , a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of... | December 8, 2022